Understanding Cancer-Associated Lambert-Eaton Myasthenic Syndrome

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with small-cell lung cancer (SCLC). This paraneoplastic syndrome affects approximately 3% of patients with SCLC but remains undiagnosed in up to 90% of cases, representing a significant clinical challenge where symptoms often overlap with expected disease progression or treatment-related adverse effects in busy oncology settings.

Dr. Iams explains that cancer-associated LEMS represents a neurologic paraneoplastic syndrome developing when patients create antibodies that cross-react between tumor antigens and neurologic targets, specifically voltage-gated calcium channels (VGCCs). This immune response, while beneficial for tumor recognition, causes collateral damage by affecting calcium channels, resulting in muscle weakness, autonomic dysfunction (most commonly orthostatic hypotension), and decreased reflexes. The patient's immune system overreacts, slowing neurologic conduction across various organ systems while attempting to fight the cancer.

LEMS belongs to the broader category of neurologic paraneoplastic syndromes, with limbic encephalitis representing another example that severely impacts personality and cognitive function through different antibody mechanisms. However, LEMS specifically involves VGCC antibodies, distinguishing it from other paraneoplastic conditions affecting patients with SCLC.

Dr. Leal addresses why oncologists miss this diagnosis despite the recognizable triad of symptoms. Dr. Iams emphasizes that newly diagnosed patients with lung cancer and their families focus primarily on fundamental cancer questions: curability, prognosis, life expectancy, and treatment expectations. These overwhelming concerns dominate initial clinic visits, often lasting hours for first-time meetings. Additionally, many patients have comorbid conditions like heart disease and lung disease that independently cause weakness, creating symptom overlap that complicates diagnosis in busy clinical environments where cancer-focused discussions take precedence.

Dr. Leal identifies key clinical indicators that raise LEMS suspicion: neurologic weakness appearing disproportionate to imaging-demonstrated disease burden, prominent proximal muscle weakness making activities like rising from chairs difficult, and subtle to significant leg-dragging sensations. These observations require heightened awareness about neurologic symptoms potentially representing cancer-related paraneoplastic syndromes. Incorporating neurologic examinations, including simple gait observation requests, can reveal significant walking abnormalities suggesting neurologic impairment and prompting LEMS consideration. However, this diagnostic awareness requires conscious clinical attention and systematic neurologic assessment practices.